Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight and maintains $6 price target.
Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target
Credit Suisse analyst Judah Frommer reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $4 price target.
Jasper Therapeutics Q4 EPS $(0.36), Inline
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 44 percent decrease over losses of $(0.25) per share from the same period last year.
EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target
EF Hutton analyst Michael King reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $6.85 price target.
EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target
EF Hutton analyst Michael King reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $6.85 price target.
Jasper Therapeutics Touts Encouraging Data From Briquilimab Conditioning In Inherited Bone Marrow Disorder
Jasper Therapeutics Inc (NASDAQ:JSPR) announced that new follow-up data from its briquilimab (formerly known as JSP191) study as a conditioning agent…
EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target
EF Hutton analyst Michael King reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $6.85 price target.
Why Nogin Shares Are Trading Higher By Around 77%; Here Are 20 Stocks Moving Premarket
Gainers
Ibio Inc (NYSE: IBIO) shares rose 162.6% to $1.97 in pre-market trading after dropping around 12% on Thursday. JMP Securities, on Thursday, downgraded iBio from Market Outperform to Market Perform.
EF Hutton Maintains Buy on Jasper Therapeutics, Maintains $4 Price Target
EF Hutton analyst Michael King maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $4 price target.
Jasper Therapeutics Announces Development Prioritization of Briquilimab In Chronic Diseases
Jasper Therapeutics Inc (NASDAQ:JSPR) will focus on developing its lead product candidate, briquilimab (formerly JSP191), in chronic diseases and stem…